› 8z8m

X-ray diffraction
2.59Å resolution

Crystal structure of human TNF alpha in complex with TNF30(VHH) domain of ozoralizumab

Released:
DOI: 10.2210/pdb8z8m/pdb
PDB entry 8z8m coloured by chain, front view.
PDB entry 8z8m coloured by chain, side view.
PDB entry 8z8m coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy.
Mima M, Mishima-Tsumagari C, Nakano K, Morimoto M, Ogata H, Sakata M, Iwaoka R, Iwata K, Hachiuma K, Iwamoto K, Fujii Y, Kurokawa T
Biochem Biophys Res Commun 734 150454 (2024)
PMID: 39083975

Function and Biology Details

Biochemical function:
Biological process:
Cellular component:

Structure analysis Details

Assembly composition:
hetero hexamer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-272043 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Tumor necrosis factor, soluble form Chains: A, C, E, G, I, K
Molecule details ›
Chains: A, C, E, G, I, K
Length: 157 amino acids
Theoretical weight: 17.37 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P01375 (Residues: 77-233; Coverage: 67%)
Gene names: TNF, TNFA, TNFSF2
Sequence domains: TNF(Tumour Necrosis Factor) family
TNF30:VHH Chains: B, D, F, H, J, L
Molecule details ›
Chains: B, D, F, H, J, L
Length: 123 amino acids
Theoretical weight: 13.72 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens

Ligands and Environments

No bound ligands
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: SPRING-8 BEAMLINE BL32XU
Spacegroup: P21
Unit cell:
a: 56.03Å b: 121.16Å c: 123.61Å
α: 90° β: 94.58° γ: 90°
R-values:
R R work R free
0.211 0.209 0.269
Expression systems:
  • Escherichia coli
  • Homo sapiens

Quick links